1
|
Aragón-Navas A, Rodrigo MJ, Garcia-Herranz D, Martinez T, Subias M, Mendez S, Ruberte J, Pampalona J, Bravo-Osuna I, Garcia-Feijoo J, Pablo LE, Garcia-Martin E, Herrero-Vanrell R. Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres. Drug Deliv 2022; 29:2357-2374. [PMID: 35904152 PMCID: PMC9341346 DOI: 10.1080/10717544.2022.2096712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
To create a chronic glaucoma animal model by a single intracameral injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (Ms) co-loaded with dexamethasone and fibronectin (MsDexaFibro). MsDexaFibro were prepared by a water-in-oil-in-water emulsion method including dexamethasone in the organic phase and fibronectin in the inner aqueous phase. To create the chronic glaucoma model, an interventionist and longitudinal animal study was performed using forty-five Long Evans rats (4-week-old). Rats received a single intracameral injection of MsDexafibro suspension (10%w/v) in the right eye. Ophthalmological parameters such as clinical signs, intraocular pressure (IOP), neuro-retinal functionality by electroretinography (ERG), retinal structural analysis by optical coherence tomography (OCT), and histology were evaluated up to six months. According to the results obtained, the model proposed was able to induce IOP increasing in both eyes over the study, higher in the injected eyes up to 6 weeks (p < 0.05), while preserving the ocular surface. OCT quantified progressive neuro-retinal degeneration (mainly in the retinal nerve fiber layer) in both eyes but higher in the injected eye. Ganglion cell functionality decreased in injected eyes, thus smaller amplitudes in PhNR were detected by ERG. In conclusion, a new chronic glaucoma animal model was created by a single injection of MsDexaFibro very similar to open-angle glaucoma occurring in humans. This model would impact in different fields such as ophthalmology, allowing long period of study of this pathology; pharmacology, evaluating the neuroprotective activity of active compounds; and pharmaceutical technology, allowing the correct evaluation of the efficacy of long-term sustained ocular drug delivery systems.
Collapse
Affiliation(s)
- Alba Aragón-Navas
- Complutense University, Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid Spain, Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain.,Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Research Institute of the San Carlos Clinical Hospital (IdISSC), Grupo de Investigación Innovación Farmacéutica en Oftalmología, Madrid, Spain
| | - María J Rodrigo
- Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza, Zaragoza, Spain.,National Ocular Pathology Network (OFTARED) Carlos III Health Institute, Madrid, Spain
| | - David Garcia-Herranz
- Complutense University, Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid Spain, Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain.,Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Research Institute of the San Carlos Clinical Hospital (IdISSC), Grupo de Investigación Innovación Farmacéutica en Oftalmología, Madrid, Spain
| | - Teresa Martinez
- Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza, Zaragoza, Spain
| | - Manuel Subias
- Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza, Zaragoza, Spain
| | - Silvia Mendez
- Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza, Zaragoza, Spain
| | - Jesús Ruberte
- Center of Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, Bellaterra, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain.,Department of Animal Health and Anatomy, School of Veterinary Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - Judit Pampalona
- Center of Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, Bellaterra, Spain.,CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain.,Department of Animal Health and Anatomy, School of Veterinary Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - Irene Bravo-Osuna
- Complutense University, Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid Spain, Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain.,Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Research Institute of the San Carlos Clinical Hospital (IdISSC), Grupo de Investigación Innovación Farmacéutica en Oftalmología, Madrid, Spain.,National Ocular Pathology Network (OFTARED) Carlos III Health Institute, Madrid, Spain
| | - Julian Garcia-Feijoo
- National Ocular Pathology Network (OFTARED) Carlos III Health Institute, Madrid, Spain.,Department of Ophthalmology, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain
| | - Luis E Pablo
- Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza, Zaragoza, Spain.,National Ocular Pathology Network (OFTARED) Carlos III Health Institute, Madrid, Spain
| | - Elena Garcia-Martin
- Instituto de Investigación Sanitaria de Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza, Zaragoza, Spain.,National Ocular Pathology Network (OFTARED) Carlos III Health Institute, Madrid, Spain
| | - Rocío Herrero-Vanrell
- Complutense University, Innovation, Therapy and Pharmaceutical Development in Ophthalmology (InnOftal) Research Group, UCM 920415, Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid Spain, Health Research Institute of the San Carlos Clinical Hospital (IdISSC), Madrid, Spain.,Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain.,Research Institute of the San Carlos Clinical Hospital (IdISSC), Grupo de Investigación Innovación Farmacéutica en Oftalmología, Madrid, Spain.,National Ocular Pathology Network (OFTARED) Carlos III Health Institute, Madrid, Spain
| |
Collapse
|
3
|
Ryu S, Park S, Lee HY, Lee H, Cho CW, Baek JS. Biodegradable Nanoparticles-Loaded PLGA Microcapsule for the Enhanced Encapsulation Efficiency and Controlled Release of Hydrophilic Drug. Int J Mol Sci 2021; 22:ijms22062792. [PMID: 33801871 PMCID: PMC7998393 DOI: 10.3390/ijms22062792] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 02/26/2021] [Accepted: 03/01/2021] [Indexed: 01/06/2023] Open
Abstract
Recently, nano- and micro-particulate systems have been widely utilized to deliver pharmaceutical compounds to achieve enhanced therapeutic effects and reduced side effects. Poly (DL-lactide-co-glycolide) (PLGA), as one of the biodegradable polyesters, has been widely used to fabricate particulate systems because of advantages including controlled and sustained release, biodegradability, and biocompatibility. However, PLGA is known for low encapsulation efficiency (%) and insufficient controlled release of water-soluble drugs. It would result in fluctuation in the plasma levels and unexpected side effects of drugs. Therefore, the purpose of this work was to develop microcapsules loaded with alginate-coated chitosan that can increase the encapsulation efficiency of the hydrophilic drug while exhibiting a controlled and sustained release profile with reduced initial burst release. The encapsulation of nanoparticles in PLGA microcapsules was done by the emulsion solvent evaporation method. The encapsulation of nanoparticles in PLGA microcapsules was confirmed by scanning electron microscopy and confocal microscopy. The release profile of hydrophilic drugs can further be altered by the chitosan coating. The chitosan coating onto alginate exhibited a less initial burst release and sustained release of the hydrophilic drug. In addition, the encapsulation of alginate nanoparticles and alginate nanoparticles coated with chitosan in PLGA microcapsules was shown to enhance the encapsulation efficiency of a hydrophilic drug. Based on the results, this delivery system could be a promising platform for the high encapsulation efficiency and sustained release with reduced initial burst release of the hydrophilic drug.
Collapse
Affiliation(s)
- Suji Ryu
- Department of Bio-Health Convergence, Kangwon National University, Chuncheon 24341, Korea;
| | - Seungyeop Park
- Department of Herbal Medicine Resource, Kangwon National University, 346 Hwangjo-gil, Dogye-eup, Samcheok-si 25949, Gangwon-do, Korea; (S.P.); (H.Y.L.); (H.L.)
| | - Ha Yeon Lee
- Department of Herbal Medicine Resource, Kangwon National University, 346 Hwangjo-gil, Dogye-eup, Samcheok-si 25949, Gangwon-do, Korea; (S.P.); (H.Y.L.); (H.L.)
| | - Hyungjun Lee
- Department of Herbal Medicine Resource, Kangwon National University, 346 Hwangjo-gil, Dogye-eup, Samcheok-si 25949, Gangwon-do, Korea; (S.P.); (H.Y.L.); (H.L.)
| | - Cheong-Weon Cho
- Institute of Drug Research and Development, College of Pharmacy, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Chungcheong, Korea
- Correspondence: (C.-W.C.); (J.-S.B.); Tel.: +82-33-540-3324 (J.-S.B.)
| | - Jong-Suep Baek
- Department of Bio-Health Convergence, Kangwon National University, Chuncheon 24341, Korea;
- Department of Herbal Medicine Resource, Kangwon National University, 346 Hwangjo-gil, Dogye-eup, Samcheok-si 25949, Gangwon-do, Korea; (S.P.); (H.Y.L.); (H.L.)
- Correspondence: (C.-W.C.); (J.-S.B.); Tel.: +82-33-540-3324 (J.-S.B.)
| |
Collapse
|